Advertisement

Drugs

, Volume 25, Supplement 2, pp 314–317 | Cite as

β-Blocker Heart Attack Trial

  • Curt D. Furberg
Section 7: Myocardial Infarction
  • 7 Downloads

Summary

The β- Blocker Heart Attack Trial (BHAT) was a National Heart, Lung, and Blood Institute-sponsored multicentre, double- blind controlled clinical trial designed to test whether the regular administration of propranolol to men and women who had experienced at least 1 documented myocardial infarction would result in a significant reduction in all-cause mortality during the follow-up period. A total of 3837 persons aged 30 to 69 years were randomised to either propranolol or placebo, 5 to 21 days after infarction. Based on serum drug level, the prescribed maintenance dose of propranolol was either 180 or 240 mg/day. BHAT was stopped 9 months ahead of schedule due to a beneficial drug effect. Total mortality during the average 25-month follow-up period was 7.2% in the propranolol group and 9.8% in the placebo group. This difference was explained by a reduction in coronary heart disease mortality, both in sudden (defined as death within 1 hour of onset of symptoms) and non-sudden death. Serious side effects were uncommon. Based on the BHAT results, the use of propranolol is recommended for at least 3 years in patients with a recent myocardial infarction, who have no contraindications to β- blockade.

Keywords

Coronary Heart Disease Mortality Practolol Alprenolol Serum Drug Level Multicentre International Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andersen, M.P.; Bechsgaard, P.; Frederiksen, J.; Hansen, D.A.; Jürgensen, H.J.; Nielsen, B.; Pedersen, F.; Pedersen-Bjergaard, O. and Rasmussen, S.L.: Effect of alprenolol on mortality among patients with definite or suspected acute myocardial infarction. Lancet 2: 865–868 (1979).PubMedCrossRefGoogle Scholar
  2. β-Blocker Heart Attack Study Group: The β-Blocker Heart Attack Trial. Preliminary report. Journal of the American Medical Association 246: 2073–2074 (1981).CrossRefGoogle Scholar
  3. β-Blocker Heart Attack Study Group: A randomized trial of propranolol in patients with acute myocardial infarction. I. Morbidity results. Journal of the American Medical Association 247: 1707–1714 (1982).Google Scholar
  4. Furberg, C.D. and Friedewald, W.T.: The effects of chronic administration of beta-blockade on long term survival following myocardial infarction; in Braunwald (Ed.) Beta-Adrenergic Blockade, a New Era in Cardiovascular Medicine, pp. 171-178 (Excerpta Medica/Elsevier dy1978).Google Scholar
  5. Multicentre International Study: Improvement in prognosis of myocardial infarction by long-term beta-adrenoreceptor blockade using practolol. British Medical Journal 3: 735–740 (1975).CrossRefGoogle Scholar
  6. Norwegian Multicentre Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. New England Journal of Medicine 304: 801–807 (1981).CrossRefGoogle Scholar
  7. O’Brien, P.C. and Fleming, T.R.: A multiple testing procedure for clinical trials. Biometrics 33: 549–556 (1979).CrossRefGoogle Scholar

Copyright information

© ADIS Press Australasia Pty Ltd (Inc. NSW) 1983

Authors and Affiliations

  • Curt D. Furberg
    • 1
  1. 1.Clinical Trials BranchNational Heart Lung and Blood InstituteBethesdaUSA

Personalised recommendations